Abstract
We isolated a tumor B-cell-targeting antibody, BI-505, from a highly diversified human phage-antibody library, using a pioneering "function-first" approach involving screening for (1) specificity for a tumor B cell surface receptor, (2) induction of tumor programmed cell death, and (3) enhanced in vivo antitumor activity compared to currently used treatments. BI-505 bound to intercellular adhesion molecule-1, identifying a previously unrecognized role for this receptor as a therapeutic target in cancer. The BI-505 epitope was strongly expressed on the surface of multiple myeloma cells from both newly diagnosed and relapsed patients. BI-505 had potent macrophage-dependent antimyeloma activity and conferred enhanced survival compared to currently used treatments in advanced experimental models of multiple myeloma.
Original language | English |
---|---|
Pages (from-to) | 502-515 |
Journal | Cancer Cell |
Volume | 23 |
Issue number | 4 |
DOIs | |
Publication status | Published - 2013 |
Bibliographical note
The information about affiliations in this record was updated in December 2015.The record was previously connected to the following departments: Division of Hematology and Transfusion Medicine (013041100), Tumour Biology, Malmö (013031300), Faculty of Medicine (000022000), Medical Inflammation Research (013212019), Oncology, MV (013035000)
Department affilation moved from v1000588 (Tumour Biology, Malmö) to v1000562 (Department of Translational Medicine) on 2016-01-18 14:39:29.
Subject classification (UKÄ)
- Cancer and Oncology